Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) understands that up to 70% of all medical decisions are based on lab tests, which account for between 3% and 6% of total patient-care costs. The amount can be even more significant if a patient requires multiple tests or if the initial test proves unforthcoming. Avricore — which is focused on developing a network of point-of-care analyzers, offering advanced technologies that aid with easy, fast and efficient diagnosis — utilizes its HealthTab(TM) platform in community pharmacies, rural areas and workplaces to cut down on the time it takes for a patient to get a proper diagnosis and medication for their ailment. The company understands the importance of proper and efficient disease diagnosis, hence its investment in point-of-care analyzers. “POC testing has proven to offer the highest cost savings, which can be traced down to the decreased cost of waiting for results,” reads a recent article. “With rapid turnaround times, patients can save between 8-20% of lab costs… With POC testing, as Avricore is currently offering, waiting can improve by as much as 46 minutes per patient, resulting in monetary savings.”
To view the full article, visit https://ibn.fm/SfWMW
About Avricore Health Inc.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM) (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.